

DAFTAR PUSTAKA

- Al-hamoudi, W. 2010. Cardiovascular changes in cirrhosis: Pathogenesis and clinical implications. *Saudi Journal of Gastroenterology*, 16(3): 145.
- Al-Jumaily, E.F. & Khaleel, F.M. 2012. The Effect of Chronic Liver Diseases on Some Biochemical Parameters in Patients Serum 1Essam. *Curr. Res. J. Biol. Sci*, 18(2): 259–266.
- Albillos, A., la Hera, A. de, González, M., Moya, J.L., Calleja, J.L., Monserrat, J., Ruiz-del-Arbol, L. & Alvarez-Mon, M. 2003. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. *Hepatology*, 37(1): 208–217.
- Albillos, A., Lario, M. & Álvarez-Mon, M. 2014. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. *J. Hepatol*, 61(6): 1385–1396.
- Alves de Mattos, A. 2011. Current indications for the use of albumin in the treatment of cirrhosis. *Annals of Hepatol*, 10: S15–S20. [http://dx.doi.org/10.1016/S1665-2681\(19\)31601-1](http://dx.doi.org/10.1016/S1665-2681(19)31601-1).
- Bataller R, B.D. 2009. A Miscellaneous, Overview of liver fibrosis. In *Gastroenterology*. Blackwell Publishing: 658 – 79.
- Benvegnù, L., Gios, M., Boccato, S. & Alberti, A. 2004. Natural history of compensated viral cirrhosis: A prospective study on the incidence and hierarchy of major complications. *Gut*, 53(5): 744–749.
- Berres, M.L., Schnyder, B., Yagmur, E., Inglis, B., Stanzel, S., Tischendorf, J.J.W., Koch, A., Winograd, R., Trautwein, C. & Wasmuth, H.E. 2009. Longitudinal monocyte Human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis. *Liver International*, 29(4): 536–543.
- Berry, P.A., Antoniadis, C.G., Carey, I., McPhail, M.J.W., Hussain, M.J., Davies, E.T., Wendon, J.A. & Vergani, D. 2011. Severity of the compensatory anti-inflammatory response determined by monocyte HLA-DR expression may assist outcome prediction in cirrhosis. *Intensive Care Med*, 37(3): 453–460.
- Cai, Y.J., Dong, J.J., Dong, J.Z., Chen, Y., Lin, Z., Song, M., Wang, Y.Q., Chen, Y.P., Shi, K.Q. & Zhou, M.T. 2017. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. *Aliment Pharmacol Ther*, 45(11): 1413–1426.
- Carvalho, M.V.H. 2019. Cirrhotic cardiomyopathy: the liver affects the heart. *Braz. J. Med. Biol. Res*, 52: 1–9.
- Cazzaniga, M., Dionigi, E., Gobbo, G., Fioretti, A., Monti, V. & Salerno, F. 2009. The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome. *Journal of Hepatology*, 51(3): 475–482.
- Chayanupatkul, M. & Liangpunsakul, S. 2014. Cirrhotic cardiomyopathy: Review of pathophysiology and treatment. *Hepatol Int*, 8(3): 308–315.

- D'Amico, G., Garcia-Tsao, G. & Pagliaro, L. 2006. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *Journal of Hepatology*, 44(1): 217–231.
- Dooley, J.S., Lok, A.S.F. & Burroughs, A.K. 2011. *Diseases of the Liver and Biliary System*. 12TH ed.
- Dultz, G., Seelhof, M., Herrmann, E., Welker, M.W., Friedrich-Rust, M., Teuber, G., Kronenberger, B., von Wagner, M., Vermehren, J., Sarrazin, C., Zeuzem, S. & Hofmann, W.P. 2013. Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis. *PLoS ONE*, 8(8): 1–6.
- Facciorusso, A., Prete, V. Del, Crucinio, N., Serviddio, G., Vendemiale, G. & Muscatiello, N. 2016. Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases. *World Journal of Gastroenterology*, 22(16): 4211–4218.
- Fattovich, G., Pantalena, M., Zagni, I., Realdi, G., Schalm, S.W. & Christensen, E. 2002. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients. *Am J Gastroenterol*, 97(11): 2886–2895.
- Friedman, S.L. 2003. Liver fibrosis-from bench to bedside. *Journal of Hepatology*, 38(81): S38–S53.
- Gaafar, A.E., Abd El-Aal, A., Alborai, M., Hassan, H.M., ElTahan, A., AbdelRahman, Y., Wifi, M.N., Omran, D., Mansour, S.A., Hassan, W.M., Ismail, M. & ElKassas, M. 2019. Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease. *Egypt. Heart J*, 71(1).
- Hajiaghhamohammadi, A.A., Daei, M.M., Zargar, A., Ahmadi-Gooraji, S., Rahban, A. & Attaran, F. 2018. Q-T interval prolongation in cirrhosis: Relationship and severity. *Caspian J Intern Med*, 9(3): 239–243.
- Ho, J.K. & Yoshida, E. 2006. The extrahepatic consequences of cirrhosis. *MedGenMed*, 8(1): 59.
- Ieranu, E.U. Ț, Onoiu, I.O.D., Strătoaie, O.C.I., Țăman, A.L.E.L.G., Ieranu, L.O.M.A. Ț, Heonea, D.A.N.O.G. & Iurea, T.U.C. 2018. Original Paper Q-T Interval Prolongation in Patients with Liver Cirrhosis. *Curr. Health Sci. J*, 44: 274–279.
- Jamil, Z. & Durrani, A.A. 2018. Assessing the outcome of patients with liver cirrhosis during hospital stay: A comparison of lymphocyte/monocyte ratio with MELD and Child-Pugh scores. *Turk J Gastroenterol*, 2018: 308–315.
- Lanzieri, P.G., Gismondi, R.A., Chimelli, M. de C.A.-R., Cysne, R.P., Guaraná, T., Mesquita, C.T. & Mocarzel, L.O. 2017. Cirrhotic Patients with Child-Pugh C Have Longer QT Intervals. *Int J Cardiovasc Sci*, 30(6): 496–503.
- Lazzerini, P.E., Capecchi, P.L. & Laghi-Pasini, F. 2015a. Long QT Syndrome: An Emerging Role for Inflammation and Immunity. *Frontiers in Cardio Med*, 2(May): 1–17.
- Lazzerini, P.E., Capecchi, P.L. & Laghi-Pasini, F. 2015b. Long QT Syndrome: An Emerging Role for Inflammation and Immunity. *J Cardiovasc Med*, 2(May): 1–17.

- Møller, S. & Bendtsen, F. 2018. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. *Liver Int*, 38(4): 570–580.
- Møller, S., Henriksen, J.H. & Bendtsen, F. 2014. Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. *World J Gastroenterol*, 20(42): 15499–15517.
- Mukherjee, P.S., Vishnubhatla, S., Amarapurkar, D.N., Das, K., Sood, A., Chawla, Y.K., Eapen, C.E., Boddu, P., Thomas, V., Varshney, S., Hidangmayum, D.S., Bhaumik, P., Thakur, B., Acharya, S.K. & Chowdhury, A. 2017. Etiology and mode of presentation of chronic liver diseases in India: A multi centric study. *PLoS ONE*, 12(10): 1–13.
- Negru, R.D., Cojocaru, D.C., Felea, M. & Trifan, A. 2017. QT interval parameters and ventricular arrhythmic events in liver cirrhosis-correlation with severity and etiology. *Biomedres*, 28(3): 1130–1134.
- Nusrat, S., Khan, M.S., Fazili, J. & Madhoun, M.F. 2014. Cirrhosis and its complications: Evidence based treatment. *World J of Gastroenterol*, 20(18): 5442–5460.
- Prabhu, S.D. 2004. Cytokine-induced modulation of cardiac function. *Circ. Res*, 95(12): 1140–1153.
- Samonakis, D.N., Koulentaki, M., Coucoutsis, C., Augoustaki, A., Baritaki, C., Digenakis, E., Papiamoni, N., Fragaki, M., Matrella, E., Tzardi, M. & Kouroumalis, E.A. 2014. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. *World J of Hepatol*, 6(7): 504–512.
- Scaglione, S., Kliethermes, S., Cao, G., Shoham, D., Durazo, R., Luke, A. & Volk, M.L. 2015. The epidemiology of cirrhosis in the United States a population-based study. *J Clin Gastroenterol*, 49(8): 690–696.
- Schuppan, D. & Afdhal, N.H. 2009. Liver Cirrhosis. *NIH*, 24(4): 838–851.
- Suva, M. 2014. A Brief Review on Liver Cirrhosis : Epidemiology , Etiology , Pathophysiology , Symptoms , Diagnosis and Its Management. *Inventi Rapid: Molecular Pharmacology*, (July): 1–5.
- Takeuchi, O. & Akira, S. 2010. Pattern Recognition Receptors and Inflammation. *Cell*, 140(6): 805–820.
- Tome, S. & Lucey, M.R. 2004. Review article: Current management of alcoholic liver disease. *Aliment Pharmacol Ther*, 19(7): 707–714.
- Triantafyllou, E., Woollard, K.J., McPhail, M.J.W., Antoniadis, C.G. & Possamai, L.A. 2018. The Role of Monocytes and Macrophages in Acute and Acute-on-Chronic Liver Failure. *Front Physiol*, 9(December): 2948.
- Tsiompanidis, E., Siakavellas, S.I., Tentolouris, A., Eleftheriadou, I., Chorepsima, S., Manolakis, A., Oikonomou, K., Tentolouris, N., Tsiompanidis, E., Siakavellas, S.I., Eleftheriadou, I. & Chorepsima, S. 2018. Liver cirrhosis-effect on QT interval and cardiac autonomic nervous system activity. *World J Gastroenterol*, 9(1): 28–36.
- Tsochatzis, E.A., Bosch, J. & Burroughs, A.K. 2014. Liver cirrhosis. In *The Lancet*. Elsevier Ltd: 1749–1761.
- Udayashankar, D. 2017. Early Detection of Cirrhotic Cardiomyopathy Using Cardiac Bio-Markers: A Cross Sectional Study. , 05(10): 28806–28812.



- Wiest, R., Lawson, M. & Geuking, M. 2014. Pathological bacterial translocation in liver cirrhosis. *J Hepatol*, 60(1): 197–209.
- Zambruni, A., Trevisani, F., Caraceni, P. & Bernardi, M. 2006. Cardiac electrophysiological abnormalities in patients with cirrhosis. *J Hepatol*, 44: 994–1002.
- Zhang, Jie, Feng, G., Zhao, Y., Zhang, Juanwen, Feng, L. & Yang, J. 2015. Association between lymphocyte-tomonocyte ratio (LMR) and the mortality of HBV-related liver cirrhosis: A retrospective cohort study. *BMJ Open*, 5(8): 1–7.